This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Roche Holding AG

Drug Names(s): Somatrem

Description: Protropin was the first recombinant growth hormone to reach the market, filling a gap left when it was determined that growth hormone harvested from cadavers carried a risk of Creutzfeldt-Jakob disease. The newer Nutropin formulations removed the initial amino acid to make the protein more similar to natural growth hormone. Protropin has similar activity to Nutropin, and has retained its indication for children with innate growth hormone deficiency. Due to lack of demand for Protropin over other growth hormone formulations, Genentech is winding down production and sales of Protropin.

Deal Structure: Protropin was originally developed by Genentech.

In March 2009, Roche and Genentech announced that they signed a merger agreement under which Roche will acquire the outstanding publicly held interest in Genentech for US95.00 per share in cash, or a total payment of approximately US$46.8 billion to equity holders of Genentech other than Roche. The acquisition was completed on March 26, 2009.

Protropin News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug